Akiyama MJ, Spaulding AC, Nijhawan AE. Long-Acting Injectable Antiretrovirals in Incarcerated Populations - Challenges and Opportunities. N Engl J Med. 2022 Nov 10;387(19):1728-1730.
Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400.
Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health. 2021 Mar 9:1-13.
Akiyama MJ, Spaulding AC, Rich JD. Flattening the Curve for Incarcerated Populations - Covid-19 in Jails and Prisons. N Engl J Med. 2020 May 28;382(22):2075-2077.
Akiyama MJ, Lipsey D, Ganova-Raeva L, Punkova L, Agyemang L, Sue A, Ramachandran S, Khudyakov Y, Litwin AH. A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy. J Infect Dis. 2020 Mar 9.
Akiyama MJ, Cleland CM, Lizcano J, Cherutich P, Kurth A. Hepatitis C Prevalence, Estimated Incidence, Risk Behaviors, and Genotypic Distribution Among People Who Inject Drugs Accessing Harm Reduction Services in Kenya: A Retrospective Cohort Study. Lancet ID. 2019 Nov;19(11):1255-1263.
Akiyama MJ, Columbus D, MacDonald R, Jordan AO, Schwartz J, Litwin AH, Eckhardt B, Carmody E. Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial. BMC Infect Dis. 2019 Aug 8;19(1):703.
Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy. Annals of Internal Medicine. 2019 Apr 9.
Spaulding AC, Graham CS, Akiyama MJ, Chhatwal J, Nijhawan AE, Ninburg MH, Rich JD, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ. HCV prevalence estimates among incarcerated persons. Hepatology. 2019 Apr 2.
Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am. 2018 Jun;32(2):347-370.
Akiyama MJ, Feffer R, Von Oehsen III WF, Litwin AH. Drug Purchasing Strategies to Treat People With Hepatitis C in the Criminal Justice System. AJPH. 2018 May;108(5):607-608.
Akiyama MJ, Agyemang L, Arnsten, JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis. 2018 Feb 9;18(1):74.
MacDonald R, Akiyama MJ, Kopolow A, Rosner Z, McGahee W, Joseph R, Jaffer M, Venters H. Full Title: Feasibility of Treating Hepatitis C in a Transient Jail Population. Open Forum Infect Dis. 2017 Jul 7;4(3):ofx142.
Akiyama MJ, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin A, Venters H, Macdonald R. Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System: Epidemiologic Patterns and Priorities for Action. Public Health Reports. 2017 Jan/Feb;132(1):41-47.
Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the “Birth Cohort” (b. 1945-1965) and younger inmates of New York City Jails. AJPH. 2016 Jul;106(7):1276-7.
Feller DJ, Akiyama MJ, Gordon P, Agins BD. Readmissions in HIV-infected Inpatients: A Large Cohort Analysis. JAIDS. 2016 Apr 1;71(4):407-12.
BardfieldJ, Agins B, Akiyama MJ, Mutandi G, Basenero A, Luphala P, Kaindjee-tjituka F, Natanael S, Hamunime N. A Quality Improvement Approach to Capacity Building in Low- and Middle-Income Countries: The case of HEALTHQUAL International. AIDS. 2015 Jul;29 Suppl2:S179-86.
Vo PK, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virologic Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences 2015 Apr;60(4):1045-51.
Akiyama MJ, Piotrowski JI, Roytman MM, Chan A, Hong LK, Huddleston L, Trujillo R, Tsai N. New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting. Hawaii Journal of Medicine and Public Health 2013 Sep;72(9 Suppl 4):6-13.